PRF1 and breast neoplasm: However, the efficacy was abrogated when treated with perforin inhibitor concanamycin, suggesting that CT exhibited the anti–breast tumor activity mainly by activating CD4+ T cells to secrete perforin (Zhou et al., 2017).